Skip to main content
Publikation AG Wehner

News categories: Publication

The role of glial IL-1R signaling in colorectal cancer

Study published in 'Nature Communications'

Interleukin-1 receptor (IL-1R) signaling plays a crucial role in the immune system, mediating inflammatory responses and maintaining homeostasis. This signaling pathway is vital for the activation and regulation of immune cells, helping the body to combat infections and other threats. However, its dysregulation has been implicated in various pathological conditions, including autoimmune diseases and cancer. One crucial player in intestinal IL-1R signaling is enteric glial cells. Enteric glia have been described as important regulators of intestinal inflammation, mediating immune responses i.e. via IL-1R. 

In colorectal cancer, IL-1R signaling has emerged as a key player in shaping the tumor microenvironment, influencing both tumor progression and the body's immune response. Understanding the precise mechanisms by which IL-1R signaling affects cancer development and progression is critical for developing targeted therapies that can modulate this pathway for better clinical outcomes.

A recent study from Sven Wehner’s group in Bonn and Gianluca Matteoli’s group from KU Leuven, Belgium, published in Nature Communications, explores the critical role of IL-1R signaling in enteric glia and their interaction with macrophages in colorectal cancer. This collaborative research discovered that IL-1R signaling in enteric glia is pivotal in promoting a pro-tumorigenic macrophage subtype. By investigating the crosstalk between enteric glial cells and immune cells, the study provides new insights into the tumor microenvironment and highlights potential therapeutic targets for colorectal cancer treatment. 

 

Abstract:

Enteric glia have been recently recognized as key components of the colonic tumor microenvironment indicating their potential role in colorectal cancer pathogenesis. Although enteric glia modulate immune responses in other intestinal diseases, their interaction with the colorectal cancer immune cell compartment remains unclear. Through a combination of single-cell and bulk RNA-sequencing, both in murine models and patients, here we find that enteric glia acquire an immunomodulatory phenotype by bi-directional communication with tumor-infiltrating monocytes. The latter direct a reactive enteric glial cell phenotypic and functional switch via glial IL-1R signaling. In turn, tumor glia promote monocyte differentiation towards pro-tumorigenic SPP1+ tumor-associated macrophages by IL-6 release. Enteric glia cell abundancy correlates with worse disease outcomes in preclinical models and colorectal cancer patients. Thereby, our study reveals a neuroimmune interaction between enteric glia and tumor-associated macrophages in the colorectal tumor microenvironment, providing insights into colorectal cancer pathogenesis.

Publication:

van Baarle, L., De Simone, V., Schneider, L. et al. 

IL-1R signaling drives enteric glia-macrophage interactions in colorectal cancer. 

Nature Communications (2024). https://doi.org/10.1038/s41467-024-50438-2

Contact:

Prof. Dr. Sven Wehner 

E-Mail: sven.wehner@ukbonn.de

Phone: (+49) 228 287 11007

Related news

Prof. Christian Strassburg, Direktor der Klinik für Allgemeine Innere Medizin am UKB, mahnt: „Die Abnehmpille ist nicht einfach nur irgendein Spaßfaktor, um jetzt ein bisschen abzunehmen!“

News categories: Publication

Weight-Loss Pill Instead of Injection: Finally, an Easy Way to Lose Weight?

As of September 1, semaglutide will be available in Germany for the treatment of overweight and obesity in tablet form for the first time. The therapy, previously known primarily as a “weight-loss injection,” can now also be taken orally. The market launch is likely to attract considerable interest – but anyone considering treatment should be aware of one thing first: the tablet is not a way to lose a few kilos, but a prescription medication for the treatment of a chronic disease.
View entry
Prof. Matthias Geyer, - together with Prof. Robert P. Fisher from New York, provides an overview of the current state of research on the transcriptional regulation of cyclin-dependent kinases (CDKs) and the prospects for cancer treatment.

News categories: Publication

A Ray of Hope in the Fight Against Cancer

Cancer is the second leading cause of death in Germany. In the search for new therapeutic approaches that target the uncontrolled growth of tumor cells, a class of enzymes known as cyclin-dependent kinases (CDKs) has come into focus. This is because this family of enzymes plays a fundamental role in gene expression and cell division. An overview of the current state of research on the transcriptional regulation of CDKs and the prospects for cancer treatment was compiled by Prof. Matthias Geyer of the UKB in collaboration with Prof. Robert P. Fisher and has now been published.
View entry
(from left) Julia Nicke and Dr. Mona Malek Mohammadi have identified a previously unknown signaling pathway in the immune system that helps newborn heart cells survive and regenerate after injury.

News categories: Publication

Central Hub for Heart Repair Discovered Bonn study: Heart muscle interaction enables cardiac regeneration in the neonatal heart

Researchers at the University Hospital of Bonn (UKB) and the University of Bonn have identified a previously unknown signaling pathway in the immune system that helps newborn heart cells survive and regenerate after injury. The findings could open new avenues for future therapies aimed at repairing damaged adult hearts after heart attacks or chronic cardiovascular disease. The study has now been published in the journal Cell Communication and Signaling (Springer Nature).
View entry

Back to the news overview